Skip to search formSkip to main contentSkip to account menu

MEN 10755

Known as: (7S,9S)-7-{(4-O-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)oxy}-6,9,11-trihydroxy-9-(hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione, MEN-10755 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

sabarubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755
AimMEN-10755 is a novel anthracycline analogue that has shown an improved therapeutic efficacy over doxorubicin in animal models… 
Review
2003
Review
2003
MEN-10755. Menarini.
Menarini is developing the anthracycline aminodisaccharide MEN-10755 for the potential treatment of solid tumors. Six phase II… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2002
2002
A phase II study of MEN-10755 in patients with advanced or metastatic ovarian cancer
2002
2002
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2000
2000
MEN-10755 appears less cardiotoxic than doxorubicin
  • 2000
  • Corpus ID: 195134069
1999
1999
A Phase I study of men-10755 in patients with a solid tumor as a shorti.v. infusion given once every 3 weeks
1999
1999
Phase I pharmacokinetic study of MEN-10755 in solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)